Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.

Zhigang Liu,Yuling Zhou,Shuang Yang,Wei-Neng Feng,Ming Yuan Chen,Xiong Zou,Guang Han,Jie Tang,Guorong Zou,Yu Xiang He,Lemeng Zhang,Lei Cui,Hualin Chen,Guo Li,Shan Jiang,Jin Gao,Lin Xiao,Qun Zhang,Wei Yi,Chenghui Huang

Olanzapine or dexamethasone, with 5-HT3 receptor antagonist and NK-1 receptor antagonist, to prevent nausea and vomiting induced by cisplatin-based doublet chemotherapy: A non-inferiority, prospective, multi-centered, randomized, controlled, phase III clinical trial.

2021

Zhigang Liu
Yuling Zhou
Shuang Yang
Wei-Neng Feng
Ming Yuan Chen
Xiong Zou
Guang Han
Jie Tang
Guorong Zou
Yu Xiang He
Lemeng Zhang
Lei Cui
Hualin Chen
Guo Li
Shan Jiang
Jin Gao
Lin Xiao
Qun Zhang
Wei Yi
Chenghui Huang

TPS12133Background: Chemotherapy-induced nausea and vomiting (CINV) is a common side effect of cancer treatments, and dexamethasone offers an advantage over placebo for protection against chemother...

Keywords:

Medicine
Nausea
Receptor antagonist
Chemotherapy
Side effect
Olanzapine
5-HT3 Receptor Antagonist
Pharmacology
Dexamethasone
Vomiting

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations